Science & Research
Canamera Energy Metals Advances São Sepé Rare Earth Project with Drill Program Underway
Canamera Energy Metals Corp. has started a 500-meter auger drill program at its São Sepé rare earth project in Brazil, targeting ionic adsorption clay-hosted mineralization across three priority areas.
BioStem Technologies to Present at LD Micro Invitational, Highlighting Regenerative Medicine Advances
BioStem Technologies will present at the 16th Annual LD Micro Invitational, showcasing its proprietary allograft technologies and expanding presence in regenerative medicine.
NHS Rolls Out One-Minute Immunotherapy Injection for Cancer Patients
The NHS in England is offering thousands of cancer patients a one-minute injection of pembrolizumab instead of a lengthy infusion, significantly reducing administration time.
OS Therapies Gains Regulatory Clarity for OST-HER2 in Osteosarcoma, Stonegate Capital Reports
Stonegate Capital Partners updates coverage on OS Therapies, highlighting EMA rolling review and TGA endpoint alignment that shift OST-HER2 toward a global approval pathway, with key survival data catalysts in 2026.
Oncotelic Therapeutics Highlighted in BioMedWire Editorial on CNS Drug Delivery Innovation
Oncotelic Therapeutics was featured in a BioMedWire editorial examining breakthroughs in central nervous system drug delivery, highlighting its proprietary intranasal nose-to-brain delivery platform that aims to overcome the blood-brain barrier for neurological diseases and biodefense applications.
SureNano Science’s GLP-1 Triple Agonist GEP-44 Targets Obesity Market as Next-Generation Therapies Gain Traction
SureNano Science Ltd. is highlighted in a BioMedWire editorial for its subsidiary GlucaPharm’s GEP-44 triple agonist peptide, which aims to improve efficacy, tolerability, and delivery flexibility in the growing GLP-1 market for obesity and metabolic diseases.
Qdrant Powers AI Platform Indexing 28 Million PubMed Abstracts to Accelerate Cancer Research
Qdrant's vector search technology enables Sapu's AI platform to index and query all 28 million PubMed abstracts, accelerating biomedical discovery and cancer research.
Aclarion Adds First Private Practice Site in Los Angeles to CLARITY Trial
Aclarion announced the addition of Lanman Spinal Neurosurgery in Beverly Hills to its CLARITY trial, expanding enrollment beyond academic centers and highlighting growing interest in Nociscan for precise chronic low back pain diagnosis.
Study Suggests Earlier Immunotherapy Could Improve Survival in Late-Stage Solid Tumors
A systematic review in JAMA Network Open indicates that earlier administration of immune checkpoint inhibitor therapies may improve survival outcomes for patients with late-stage solid tumors, though further validation is needed.
SureNano Science Launches IND-Enabling Program for Obesity and Diabetes Drug GEP-44, Targeting a $200 Billion Market
SureNano Science has initiated an FDA-aligned GLP toxicology and pharmacology program for its lead candidate GEP-44, a multi-receptor peptide for obesity and type 2 diabetes, positioning the company to enter the rapidly growing GLP-1 market projected to reach $200 billion by 2030.
Delta Gold Technologies Featured in Debut Episode of The Innovation Report Series on Quantum Technologies
Delta Gold Technologies PLC is featured in the first episode of The Innovation Report Series, highlighting the commercial potential of quantum technologies and their impact across industries.
HeartBeam Launches Pilot Study for On-Demand 12-Lead ECG Patch Aimed at Ischemia Detection
HeartBeam Inc. has initiated a pilot study for its investigational on-demand 12-lead ECG patch in coronary artery disease patients, potentially expanding ambulatory cardiac monitoring into ischemia detection within a $2 billion market.
NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship
NanoViricides points to its clinical-stage antiviral candidate NV-387 as a potential broad-spectrum therapeutic following an Andes hantavirus incident aboard a cruise ship, underscoring the need for versatile antiviral treatments.
Oncotelic Therapeutics Targets CNS Drug Delivery as Brain Therapeutics Innovation Accelerates
Oncotelic Therapeutics is leveraging its intranasal nose-to-brain delivery platform to address the challenge of delivering therapeutics across the blood-brain barrier, targeting Alzheimer's disease and biodefense applications in a rapidly evolving biopharma landscape.
SureNano Science Advances GEP-44 as Obesity Drug Market Poised to Exceed $200 Billion
SureNano Science Ltd., through its subsidiary GlucaPharm Inc., is developing GEP-44, a next-generation GLP-1 triple agonist peptide targeting obesity and metabolic disorders, as the global market for such therapies is projected to surpass $200 billion.
SureNano Science Advances Next-Generation GLP-1 Platform with Triple Agonist Peptide GEP-44
SureNano Science Ltd. is developing GEP-44, a novel triple agonist peptide for improved GLP-1 therapy, aiming to address obesity and diabetes alongside major players like Eli Lilly and Novo Nordisk.
CNS Drug Delivery Innovations Address Critical Bottleneck in Biotech Market
Advancements in blood-brain barrier penetration technologies, such as Oncotelic's intranasal nose-to-brain system, are unlocking significant opportunities in the biotech sector by enabling targeted CNS therapies for diseases like Alzheimer's and bolstering biodefense preparedness.
AI System Detects Pancreatic Cancer Signs Three Years Before Diagnosis
Mayo Clinic researchers have developed an AI system that identifies early warning signs of pancreatic cancer up to three years before formal diagnosis, potentially enabling earlier intervention and improved outcomes.
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provisional patent application.
NanoViricides to Present at D. Boral Capital Global Conference Amid Progress on Broad-Spectrum Antiviral NV-387
NanoViricides will participate in the D. Boral Capital Global Conference, highlighting its clinical-stage antiviral drug NV-387 and its potential to treat multiple viral infections including RSV, COVID, and Monkeypox.
Annovis Bio CEO to Present Multi-Protein Approach to Alzheimer's at Fierce Biotech Week 2026
Annovis Bio CEO will present the company's multi-protein targeting strategy for Alzheimer's disease at Fierce Biotech Week 2026, highlighting buntanetap's Phase 3 trial.
Wellness Index Report Reveals Top Providers in Superhuman Protocol Challenge, Marking Shift to Cellular-Level Health
The April 2026 Wellness Index Report identifies Physical Evidence Chiropractic, Boro Holistic Health, and April Berkowitz as leading providers in the Superhuman Protocol Challenge, signaling a move from seasonal weight-loss trends to system-level health optimization.
Oncotelic Therapeutics Completes $12.5M Asset Transfer to Lunai Bioworks, Focusing on Nose-to-Brain Delivery for Alzheimer's and Biodefense
Oncotelic Therapeutics has transferred worldwide rights to its nose-to-brain delivery system for Alzheimer's and biodefense to Lunai Bioworks in exchange for $12.5 million in preferred stock, enabling it to monetize assets while retaining control for other indications like Parkinson's disease.
Blocking Fructose Metabolism Shows Promise Against Pediatric Brain Cancer
New research from Johns Hopkins reveals that disrupting fructose metabolism in tumor cells could slow group 3 medulloblastoma, a deadly childhood brain cancer, offering a potential new treatment avenue.
Canamera Energy Metals Engages ExploreTech to Optimize Drilling at Schryburt Lake REE-Niobium Project
Canamera Energy Metals Corp. has hired ExploreTech for an independent geophysical review and drill optimization at its Schryburt Lake REE-Niobium Project in Ontario, aiming to refine targets and expedite a 1,500-meter drilling program pending permit approval.
VolitionRx Reports High Accuracy in Feline Cancer Blood Test, Unlocking $5M Milestone
VolitionRx's Nu.Q Vet prototype assay shows 97% specificity in detecting feline lymphoma, advancing a liquid biopsy for cats and unlocking a $5 million contractual milestone upon peer-reviewed publication.
New Study Reveals How Cancer Reprograms Immune Cells, Offering Hope for Immunotherapy Breakthrough
A study uncovering how cancer cells reprogram immune cells to support tumor growth could improve immunotherapy response rates, which currently fail in 80% of patients.
MilliporeSigma Expands Temecula Biotech Hub, Advancing Organoid Research and Personalized Medicine
MilliporeSigma's investments in Temecula, including a new organoid lab and acquisition of HUB Organoids, position the site at the forefront of disease modeling and personalized medicine, while reinforcing its community commitment.
Oragenics Advances Phase IIa Trial for Concussion Treatment, Targeting Data Readout by 2026
Oragenics Inc. is actively enrolling patients at a second site in its Phase IIa trial for ONP-002, a potential first-in-class treatment for concussion, with a data readout expected by end of 2026.
Aclarion Expands Nociscan Use at Weill Cornell Medicine in New Trial on Disc Degeneration
Aclarion's second commercial agreement with Weill Cornell Medicine will deploy its Nociscan platform in a randomized controlled trial led by Dr. Roger Härtl, aiming to improve understanding and treatment of degenerative disc disease.